Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Citron

Long Bitcoin, Short MicroStrategy: Citron Research 'Proud Of The Timing' One Year Later

Short seller Citron Research, led by Andrew Left, made a prediction one year ago. The firm bet on Bitcoin (CRYPTO: BTC), but against the Bitcoin treasury company Strategy Inc (NASDAQ:MSTR). Here are the results of the trade.

Trump Just Made This The 'Most Important Company In America,' Says Andrew Left: 'That Nobody's Heard Of...'

Trump Just Made This The 'Most Important Company In America,' Says Andrew Left: 'That Nobody's Heard Of...'

Andrew Left’s Citron Research is calling out a little-known nuclear contractor, which it says is about to become one of the most strategically significant companies in the United States under the Trump administration.

What's Going On With Bleichroeder Acquisition Corp (BACQ) Stock Today?

What's Going On With Bleichroeder Acquisition Corp (BACQ) Stock Today?

Bleichroeder Acquisition Corp (NASDAQ:BACQ) shares are trending higher Thursday following commentary from Citron Research highlighting the SPAC’s risk-reward profile.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Churchill Capital Corp X (CCCX) Stock Jumps On Infleqtion, Silicon Light Machines Partnership

Churchill Capital Corp X (NASDAQ:CCCX) shares are trading higher Thursday after Infleqtion, the quantum computing firm set to merge with Churchill’s special purpose acquisition company (SPAC), announced a partnership with Silicon Light Machines to enhance its quantum computing technology.

Rigetti Vs. Infleqtion: Citron Weighs In On Quantum 'Raging Bulls'

Citron Research's assessment of Rigetti Computing Inc. (NASDAQ:RGTI) versus Infleqtion, the quantum technology firm set to merge with Churchill Capital Corp X (NASDAQ:CCCX), has "raging" quantum bulls locking horns.

Why Teladoc Health (TDOC) Stock Is Trading Higher Wednesday

Shares of Teladoc Health Inc (NYSE:TDOC) are trading higher and trending Wednesday afternoon. Here’s what investors need to know.

Churchill Capital Corp X (CCCX) Stock Soars As Citron Highlights Quantum Opportunity The Market Is Missing

Shares of Churchill Capital Corp X (NASDAQ:CCCX) are rising Monday after a notable research firm expressed optimism for the quantum computing technology company on social media.

inkl

Read news from The Economist, FT, and more,
with one subscription

Teladoc (TDOC) Shares Climb On Bullish Commentary From Citron Research

Teladoc (TDOC) Shares Climb On Bullish Commentary From Citron Research

Shares of Teladoc Health Inc (NYSE:TDOC) are surging Friday morning after Citron Research posted bullish comments on the telehealth provider, asserting they were “not wrong, just early” on the stock’s potential. The commentary sparked renewed investor interest, pushing the stock higher in early trading.

Cardlytics Stock Surges 5% After Hours As Citron Research Spotlights Wells Fargo Partnership

Cardlytics Stock Surges 5% After Hours As Citron Research Spotlights Wells Fargo Partnership

Cardlytics Inc. (NASDAQ: CDLX) saw its stock fall 9.85% during regular trading on Thursday. However, the stock rebounded in after-hours trading, climbing 5.04% to $2.50 following positive remarks from analysts.

Cardlytics Stock Soars After Citron Research Says Shares Could 'Double Or Triple' From Here

Cardlytics Stock Soars After Citron Research Says Shares Could 'Double Or Triple' From Here

Shares of Cardlytics, Inc. (NASDAQ:CDLX) are rising on Wednesday after a research firm published a glowing report on the company, which partners with retail outlets and banks to offer cash-back rewards on card purchases.

Cardlytics (CDLX) Stock Soars Over 50% On AmEx News And Citron Tweet

Cardlytics (CDLX) Stock Soars Over 50% On AmEx News And Citron Tweet

Shares of advertising-platform Cardlytics Inc (NASDAQ:CDLX) are surging Thursday morning. The rally was ignited by a bullish tweet from Citron Research connecting Cardlytics to news of the American Express Co (NYSE:AXP) Platinum card refresh.

Trump-Linked Mortgage Trade? Citron Says This Stock Is A Soldier In 'War On Housing' — Predicts 91% Upside

Trump-Linked Mortgage Trade? Citron Says This Stock Is A Soldier In 'War On Housing' — Predicts 91% Upside

Andrew Left’s Citron Research is making a bold new bet in the housing finance space, framing it as a deep-value play, and one that is likely to play a central role in President Donald Trump’s new housing policy.

Short Seller Andrew Left Recalls Bet On Nebius As It Soars Over 130% In 2025: 'Just A Pat On The Back' From When NBIS Was At $20 Per Share

Short Seller Andrew Left Recalls Bet On Nebius As It Soars Over 130% In 2025: 'Just A Pat On The Back' From When NBIS Was At $20 Per Share

Famed short-seller Andrew Left of Citron Research is taking a victory lap on a bullish call, celebrating his firm’s early bet on AI infrastructure company Nebius Group NV (NASDAQ:NBIS).

Martin Shkreli Doubles Down On Opendoor 'Short' Call: 'Pharma-Bro' Draws Parallels With Newegg — 'Game Over Losers'

Martin Shkreli Doubles Down On Opendoor 'Short' Call: 'Pharma-Bro' Draws Parallels With Newegg — 'Game Over Losers'

Former hedge fund manager and pharmaceutical executive, Martin Shkreli, doubled down on his bearish stance against Opendoor Technologies Inc. (NASDAQ:OPEN), drawing parallels with another retail favorite stock that has since witnessed a pullback.

Get all your
news in one place.

100’s of premium titles.
One news app.

Opendoor Attacked By Short Seller—Stock Pops Anyway

Citron Research, led by famed short-seller Andrew Left, targeted Opendoor Technologies, Inc. (NASDAQ:OPEN) in a social media post on Friday. Opendoor investors shrugged off the attack, and the stock climbed.

What's Going On With Palantir Stock?

Shares of Palantir Technologies Inc (NASDAQ:PLTR) continue to face selling pressure following an AI-powered rally in recent months. Here’s a look at what’s going on.

Palantir's AI Edge: PEG Ratio Outshines Salesforce—'Sleeper Valuation' Defying P/E Skeptics?

In a landscape where high Price-to-Earnings (P/E) ratios often scare investors, a different metric defies skeptics that AI powerhouse, Palantir Technologies Inc. (NASDAQ:PLTR), which was battered last week for its high valuations following a Citron Research report, is not quite overpriced.

How AI darling Palantir became the S&P 500’s best and worst stock of 2025, climbing 144% before shedding value in 6 straight sessions

Over $73 billion has been wiped off high-flying Palantir’s market cap in recent days.

Get all your
news in one place.

100’s of premium titles.
One news app.

PLTR Stock Has Declined Over 15% In Past 5 Sessions, But This Tech Bull Says Palantir Remains 'Favorite'

Despite a sharp sell-off that has seen Palantir Technologies Inc. (NYSE:PLTR) shares plummet nearly 15% in the last five sessions, Wedbush Securities analyst Dan Ives is urging investors to see the dip as a buying opportunity.

Palantir Leads Tech Stock Slide: 52% Of Retail Investors Say No AI 'Bubble'

Many large tech stocks are falling this week, led lower by retail darling Palantir Technologies, Inc. (NASDAQ:PLTR). Has the recent surge in AI stocks gone too far, too fast?

Palantir Short Seller Andrew Left's Citron Now Compares It To Databricks: 'PLTR Is A $40 Stock, And Every Real AI Leader Keeps Reminding Us'

Short-seller Andrew Left‘s Citron Research intensified its campaign against Palantir Technologies Inc. (NYSE:PLTR) on Wednesday, posting a direct comparison to private competitor Databricks that highlights Palantir’s slower growth on several key metrics.

Palantir Continues To Decline In Pre-Market As Valuation Concerns Mount—Citron Research Targets Overvaluation

Palantir Technologies Inc. (NASDAQ:PLTR) declined 0.95% to $156.08 during pre-market on Wednesday, extending its 9.35% drop from Tuesday's regular trading, despite expanding its partnership with Fujitsu Ltd.

Short Seller Andrew Left Says 'OpenAI At $500 Billion Puts Palantir At $40' — And That's Generous

Renowned short-seller Andrew Left's Citron Research has issued a bearish report on Palantir Technologies Inc. (NASDAQ:PLTR), arguing the stock is significantly overvalued and its price is "detached from fundamentals and analysis".

Citron Research Just Warned AGAIN on Palantir. How Should You Play PLTR Stock Here?

Citron Research says Palantir stock at $40 per share would still be an expensive AI stock to own. Wall Street recommends caution on PLTR shares as well.

What's Going On With Palantir Technologies (PLTR) Stock?

Palantir Technologies Inc (NASDAQ:PLTR) shares have become a focal point of market debate in recent sessions as a new short-seller report clashes with bullish catalysts from government and enterprise sectors. Here’s what investors need to know.

People

155,780 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

American Express

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

324,930 stories

The United States

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play